Anti-Von Willebrand Factor 抗体 - Aminoterminal end (ab47160)


  • 製品名Anti-Von Willebrand Factor antibody - Aminoterminal end
    Von Willebrand Factor 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to Von Willebrand Factor - Aminoterminal end
  • 特異性This antibody recognizes the 2,813 and 2,752 amino acid forms of Von Willebrand Factor, but only a portion of the 2,764 amino acid form.
  • アプリケーション適用あり: WBmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Synthetic peptide based on the aminoterminal end of full length Human Von Willebrand Factor.



Our Abpromise guarantee covers the use of ab47160 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
  • 追加情報WB: 1/1000 - 1/5000. Predicted molecular weight: 309 kDa. A recommended starting concentration for Western blots is 1/1000 when using colorimetric substrates such as BCIP/NBT, and 1/5000 for chemiluminescent substrates. Notes: Many bands of varying sizes can be seen on Western blots, perhaps indicating differential processing by ADAMTS13 and other enzymes. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
    • 組織特異性Plasma.
    • 関連疾患Defects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
    • 配列類似性Contains 1 CTCK (C-terminal cystine knot-like) domain.
      Contains 4 TIL (trypsin inhibitory-like) domains.
      Contains 3 VWFA domains.
      Contains 3 VWFC domains.
      Contains 4 VWFD domains.
    • ドメインThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
    • 翻訳後修飾All cysteine residues are involved in intrachain or interchain disulfide bonds.
      N- and O-glycosylated.
    • 細胞内局在Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
    • Information by UniProt
    • 参照データベース
    • 別名
      • Coagulation factor VIII antibody
      • Coagulation factor VIII VWF antibody
      • F8VWF antibody
      • Factor VIII related antigen antibody
      • von Willebrand antigen 2 antibody
      • von Willebrand antigen II antibody
      • Von Willebrand disease antibody
      • VWD antibody
      • vWF antibody
      • VWF_HUMAN antibody
      see all

    Anti-Von Willebrand Factor antibody - Aminoterminal end 画像

    • All lanes : Anti-Von Willebrand Factor antibody - Aminoterminal end (ab47160) at 1/1000 dilution

      Lane 1 : Human serum reduced sample buffer at 1 µl
      Lane 2 : Human serum reduced sample buffer at 0.5 µl
      Lane 3 : Human serum reduced sample buffer at 0.25 µl

      Predicted band size : 309 kDa
      Observed band size : 170,302 kDa (why is the actual band size different from the predicted?)


    Anti-Von Willebrand Factor antibody - Aminoterminal end (ab47160) 使用論文

    ab47160 has not yet been referenced specifically in any publications.

    Product Wall

    Vielen Dank für Ihren Anruf.

    Nachdem ich wie versprochen alle unsere Von Willebrand Faktor- Antikörperdaraufhin untersucht habe, ob sie möglicherweise die Bindung von Faktor VIII inhibieren können, weiß ich nicht, ob...

    Read More

    This one may not be as simple as the last, the only antibody I have found
    that we know recognizes the region the customer is targetting is ab47160.
    But on the datasheet, it says that it only recognizes the 5813 &2752 forms of vWF,

    Read More

    We have antibodies against CD34 and CD105 that are known to be reactive with the human CD antigens, but non-reactiivity with mouse CD antigens is more difficult to demonstrate consistently. We do not have any antibodies against these proteins (or other...

    Read More

    I just found the homology information for the immunogen for ab47160: It is 74% homolog with mouse. The antibody might not crossreact with mouse, but we cannot guarantee it as this has not yet been tested. I hope this is of help. Please let me know if y...

    Read More

    Thank you for contacting us. All 3 antibodies were raised against the human full length protein. I checked the homology with the mouse full length protein and it is 83%. Cross reactivity might therefore be likely, but has not been tested. Since we do n...

    Read More

    Thank you for your patience. I have gathered all the information for the vWF protein. As I mentioned in my recent email, the homology between human and mouse vWF full length proteins is 83%. Most of our antibodie have been raised against full lengt...

    Read More

    Thank you for calling Abcam earlier. I have heard back from the lab about ab47160, Anti-Von Willebrand Factor antibody - Aminoterminal end. They have told me that there is a 74% degree of homology between the immunogen sequence used to generate this an...

    Read More